Intravenous (IV) Human Albumin in Critical Care: When, Why & Which?
Intravenous (IV) human albumin plays a well-established role in critical care through its ability to restore and maintain intravascular volume when a colloid is clinically indicated. Beyond plasma expansion, albumin contributes to maintaining oncotic balance, facilitating molecular transport, providing antioxidant activity, and modulating coagulation. Its clinical value lies in its prudent, indication-driven use, particularly in scenarios of proven volume deficit or circulatory dysfunction, where evidence supports meaningful hemodynamic and outcome benefits. , This article examines when albumin therapy is warranted in critical care settings, why its unique properties matter in specific clinical contexts, and which formulations may optimally serve evidence-based indications in real-world practice settings.
Clinical Rationale & Potential Benefits of IV Albumin Beyond Volume Expansion
Albumin exerts pleiotropic effects beyond volume expansion: glycocalyx protection preventing endothelial degradation, inhibition of endothelial apoptosis via PI3K-dependent pathways, nitric oxide modulation through S-nitrosothiol formation, and antioxidant activity via cysteine-34 scavenging of reactive oxygen species. These mechanisms translate to organ-protective signals, preserving endothelial integrity during ischemia-reperfusion, enhancing coronary flow, maintaining colloid osmotic pressure-pulmonary artery wedge pressure (COP-PAWP) gradients, and providing drug-binding capacity at Sudlow sites (drug binding sites on albumin) for pharmacokinetic modification. Clinical evidence demonstrates albumin’s disease-modifying potential in septic shock, decompensated cirrhosis, and cardiac surgery through mechanisms independent of oncotic effects, establishing its role as a biological therapeutic beyond resuscitation fluid.
When to Consider Intravenous Albumin? Key Clinical Scenarios
Hypovolemia with Hypoalbuminemia Unresponsive to Crystalloids: An RCT (n=26) in patients with hypovolemic and septic shock demonstrated albumin achieved target pulmonary artery wedge pressure (~12 mmHg) with 2-4 fold less volume than crystalloids while preserving the colloid osmotic pressure-pulmonary artery wedge pressure (COP-PAWP) gradient.
Sepsis and Septic Shock: Meta-analysis of 17 RCTs (n=1,977) demonstrated 18% reduced mortality risk with albumin versus other fluids (albumin 29% vs controls 34%; OR 0.82). When comparing albumin to crystalloids (seven trials, n=1,441), mortality reduction was 22% (OR 0.78), supporting Surviving Sepsis Campaign guidelines.
Liver Cirrhosis Associated Complications: The ANSWER trial (n=440) demonstrated long-term albumin reduced 18-month death/TIPS/transplantation risk by 38% (HR 0.62) while decreasing paracentesis need by 54%; evidence supporting AASLD/EASL recommendations for albumin in large-volume paracentesis, spontaneous bacterial peritonitis, and hepatorenal syndrome type-1 prevention in decompensated cirrhosis
Survival Outcomes in Burn Care: A retrospective cross-sectional study (n=486) demonstrated serum albumin levels above 2 g/dL reduced mortality risk by approximately 80%, establishing albumin as both a sensitive marker of burn severity and predictor of survival outcomes. In adult burn shock resuscitation, albumin infusion within the first 24 hours was associated with a 66% reduction in mortality (OR 0.34) and an 81% reduction in compartment syndrome (OR 0.19), suggesting that albumin improves burn shock resuscitation.
AKI Risk in Critically Ill Patients: Meta-analysis of 11 RCTs (n=1,220) across ascites, surgery, sepsis, and spontaneous bacterial peritonitis demonstrated hyperoncotic albumin reduced AKI risk by 76% (OR 0.62; 95% CI 0.28-0.95) compared to crystalloids and other colloids. The same analysis showed hyperoncotic albumin reduced mortality by 48% (OR 1.41; 95% CI 1.05-1.96), establishing its renoprotective role in critically ill patients with hypoalbuminemia—a recognized risk factor for AKI development.
Postoperative and Complex ICU Fluid Management: A comparative study in orthotopic liver transplant patients (n=30) demonstrated that continuous albumin infusion (100 g/day for seven days) significantly reduced Sequential Organ Failure Assessment (SOFA) scores compared to controls (11.0±3.6 vs 13.4±3.7; p<0.001), indicating less multi-organ dysfunction in the albumin group, supporting albumin’s role in postoperative fluid management for complex surgeries.
Real-World Challenges: Safety and Practical Considerations
Modern albumin preparations demonstrate strong safety through effective viral inactivation, though formulation-related factors remain clinically relevant. Manufacturing processes often alter effective albumin concentration and biological actions, making iso-oncotic and hyperoncotic preparations distinct therapeutic entities. Sodium content variability influences osmolarity, while inappropriate administration may precipitate pulmonary or cerebral edema, particularly in traumatic brain injury. Practice variability and cost constraints continue to complicate real-world use despite available guidelines.2
Choosing the Right Albumin: Quality and Safety Imperatives
Albumin selection should be guided by manufacturing standards, pathogen safety protocols, and formulation characteristics that influence clinical outcomes. Products complying with the IQPP (International Quality Plasma Protein Program) and QSEAL (Quality Standards of Excellence, Assurance, and Leadership) frameworks incorporate multiple pathogen-reduction steps during plasma collection and fractionation. Container design also matters; closed infusion systems may help reduce CLABSIs (Central Line-associated Bloodstream Infection), while modern flexible containers, avoid PVC-related contamination and allow room-temperature storage. Hyperoncotic 25% albumin enables concentrated volume expansion for indication-specific use in hypovolemia, liver disease, transplantation, and septic shock.
Take-Home Messages and the Way Forward
● Intravenous human albumin is more than a volume expander, exerting endothelial-protective, antioxidant, and immunomodulatory effects that support organ function in critical illness.
● Clinical trials and guideline-supported evidence demonstrate benefit in selected settings, including hypovolemia unresponsive to crystalloids, septic shock, decompensated cirrhosis and related complications, major or transplant surgery, burn care, acute kidney injury risk, and complex ICU fluid management, when appropriately indicated.
● Optimal outcomes depend on indication-driven use of high-quality, well-regulated albumin products, with attention to formulation, manufacturing standards, and safety-focused delivery systems.
Abbreviations: AASLD – American Association for the Study of Liver Diseases, AKI – Acute Kidney Injury, ANSWER – The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis, CLABSI – Central Line-Associated Bloodstream Infection,COP – Colloid Osmotic Pressure, EASL – European Association for the Study of the Liver, HES – Hydroxyethyl Starch, HR – Hazard Ratio, ICU – Intensive Care Unit, IQPP – International Quality Plasma Protein Program, LVP – Large-Volume Paracentesis, OR – Odds Ratio, PAWP – Pulmonary Artery Wedge Pressure, PI3K – Phosphoinositide 3-Kinases, PVC – Polyvinyl Chloride, PVDC – Polyvinylidene Chloride, QSEAL – Quality Standards of Excellence, Assurance, and Leadership, RCT – Randomized Controlled Trial, SBP – Spontaneous Bacterial Peritonitism, SOFA – Sequential Organ Failure Assessment, TIPS – Transjugular Intrahepatic Portosystemic Shunt
